| Drug Name |
Dalfampridine |
| Drug ID |
BADD_D00574 |
| Description |
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010. |
| Indications and Usage |
Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS). |
| Marketing Status |
approved |
| ATC Code |
N07XX07 |
| DrugBank ID |
DB06637
|
| KEGG ID |
D04127
|
| MeSH ID |
D015761
|
| PubChem ID |
1727
|
| TTD Drug ID |
D08YIN
|
| NDC Product Code |
10144-427; 63190-0510; 67877-444; 56125-427; 0591-2533; 65862-917; 62756-429; 63629-9450; 65862-863; 38779-3205; 42571-338; 51927-5030; 42571-275; 0378-4504; 12817-054; 46016-5042; 54382-125; 62756-038; 62991-3143; 65372-1157; 16729-292; 63190-0530; 51407-246; 0054-0479 |
| UNII |
BH3B64OKL9
|
| Synonyms |
4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR |
